This study shows that high expression of CARM1 in multiple myeloma patients, especially in stage III or relapsed refractory MM, is strongly associated with poor prognosis; CARM1 knockdown activates the p53 signaling pathway and inhibits MM cell proliferation. Here, CARM1 is linked to Miyoshi myopathy.